Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asperum: acetylsalicylic acid to prevent severe COVID-19 pneumonia in hospitalized patients
2020-006130-12Phase 3Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and viral pneumonia comparing Acetylsalicylic acid with Placebo (2 arms). Primary endpoint: Primary composite endpoint. Started Feb 2021; status: terminated.
02
Drugs
aspirin
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-006130-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006130-12.